Cargando…
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
Autores principales: | Bahçecíoğlu, Ömer Faruk, Gök, Selim, Durmuş, Mefküre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907691/ https://www.ncbi.nlm.nih.gov/pubmed/33472816 http://dx.doi.org/10.1136/ejhpharm-2021-002680 |
Ejemplares similares
-
Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022) -
Immune checkpoint inhibitors: use them early, combined and instead of TACE?
por: De Toni, Enrico N
Publicado: (2020) -
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer
por: Iorio, Vittoria, et al.
Publicado: (2018) -
Proton pump inhibitor use associated with changes in gut microbiota composition
por: Reveles, Kelly R, et al.
Publicado: (2018) -
Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case–control study
por: Xiong, Jianping, et al.
Publicado: (2020)